BTIG Reiterates Buy on Carlsmed, Maintains $23 Price Target
BTIG analyst Ryan Zimmerman reiterates Carlsmed (NASDAQ:CARL) with a Buy and maintains $23 price target.
Share
Why It Matters
An analyst who studies stocks says Carlsmed is a good buy. The analyst thinks the stock could be worth $23 per share.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.